Core Viewpoint - Microbix Biosystems Inc. reported Q1 revenues of $4.2 million, indicating a recovery in revenue growth following previous client setbacks [1] Financial Performance - The company achieved a revenue growth of 13% compared to Q4 fiscal 2025, demonstrating efforts to rebuild revenues above the breakeven point [1] - The controlled net loss indicates improved financial management and operational efficiency [1]

Core Viewpoint - Microbix Biosystems Inc. is presenting its novel Quality Assessment Products and platform technology aimed at enhancing quality management and reproducibility in Molecular Pathology diagnostics at an upcoming lab diagnostics conference in Helsinki, Finland [1] Group 1: Company Overview - Microbix Biosystems Inc. is identified as a life sciences innovator, manufacturer, and exporter [1] Group 2: Industry Context - The presentation focuses on Molecular Pathology, which combines traditional pathology with nucleic acid analysis for diagnosing infectious diseases [1]

Core Viewpoint - Microbix Biosystems Inc. has updated its investor presentation to clarify its use of EBITDA in response to comments from the Ontario Securities Commission (OSC) regarding non-IFRS financial measures [1] Group 1: Company Actions - The company has revised its investor presentation on its corporate website to address OSC staff comments [1] - The OSC's review highlighted that Microbix referred to EBITDA in two slides of its investor-oriented PowerPoint presentation [1]

Core Viewpoint - Microbix Biosystems Inc. reported a significant decline in revenues for the fiscal year 2025, primarily due to reduced antigen sales into China and the cancellation of a client program, resulting in a net loss of $2.2 million [1][3][6]. Financial Performance - Total revenues for 2025 were $18.6 million, a 27% decrease from $25.4 million in 2024 [3]. - Antigen revenues decreased by 10% to $12.4 million, attributed to fewer respiratory infections in China [3]. - QAPs revenues fell by 20% to $5.6 million due to the cancellation of test-development programs by a large client [3]. - Revenue from royalties increased by 15% to $598,775 [3]. - Gross margin percentage for 2025 was 53%, down from 61% in 2024, mainly due to fixed manufacturing costs being spread over fewer units [4]. - Operating expenses increased by 4% in 2025, influenced by lower investment income and increased spending on trade shows and R&D [5]. Quarterly Performance - Q4 revenue was $3.7 million, a 41% decrease from $6.3 million in Q4 2024 [8]. - Antigen sales in Q4 dropped by 55% to $1.95 million, primarily due to weaker sales to the China distributor [8]. - QAPs revenues in Q4 decreased by 5% to $1.6 million [8]. - Q4 gross margin percentage was 40%, down from 55% in the previous year [9]. - The company reported a net loss of $1.5 million in Q4 compared to a net income of $440,324 in Q4 2024 [10]. Cash Flow and Financial Ratios - Cash used in operating activities for 2025 was $80,287, a significant decline from cash provided of $4.3 million in 2024 [6]. - Cash and equivalents at the end of September 2025 were $12.1 million [6]. - The current ratio was 8.48, indicating strong liquidity, while the debt to equity ratio remained stable at 0.35 [7]. Corporate Outlook - The company is focused on pursuing new client programs and expanding its product portfolio to drive sales growth and improve gross margins [13]. - Microbix aims to create sustained shareholder value through its diagnostics business and the Kinlytic® drug program [13].

Core Insights - Microbix Biosystems Inc. is set to release its Q4 2025 financial results on December 18, 2025, prior to market opening, followed by a webinar discussion with key executives [1] Company Overview - Microbix Biosystems Inc. specializes in proprietary biological products for human health, employing over 120 skilled workers and reporting revenues of C$ 25.4 million in the last fiscal year (2024) [3] - The company supports the global diagnostics industry by providing critical ingredients and devices, including antigens for immunoassays and laboratory quality assessment products (QAPs™) [3] - Microbix's products are utilized by approximately 100 diagnostics manufacturers, and its QAPs are available in over 30 countries through a network of international distributors [3] - The company is accredited with ISO 9001 & 13485, registered with the U.S. FDA, Australian TGA, and licensed by Health Canada, ensuring compliance with IVDR and CE marking [3] Product Development - Microbix also develops proprietary products such as Kinlytic® urokinase, a thrombolytic drug for treating blood clots, and reagents for molecular diagnostic testing [4]

Core Insights - Microbix Biosystems Inc. has launched QAPs™ quality assessment products and QUANTDx™ reference materials to support testing for H3N2 strains of seasonal Influenza A [1] Group 1: Product Launch and Features - The new QAPs™ are designed to assist in the detection of H3N2 variants, which are becoming dominant in the 2025/26 Flu season, and are crucial for accurate disease management [3][4] - Microbix's QAPs provide multi-year room-temperature stability and are available in PROCEEDx® (RUO) and REDx® (IVD) variants, catering to different user needs [4] - QUANTDx products are characterized as accurately-quantified and fully-traceable reference materials that help assay developers establish key analytical performance metrics [5] Group 2: Company Overview - Microbix Biosystems Inc. reported revenues of C$ 25.4 million in its latest fiscal year (2024) and employs over 120 skilled personnel [7] - The company specializes in creating biological products for human health, including antigens for immunoassays and laboratory quality assessment products [7] - Microbix's QAPs are now available in over 30 countries, supported by a network of international distributors, and the company holds various accreditations including ISO 9001 & 13485 [7][8]

Core Viewpoint - Microbix Biosystems Inc. has announced a Normal Course Issuer Bid (NCIB) program to repurchase up to 5% of its outstanding shares over a 12-month period, starting December 9, 2025, and ending December 8, 2026 [1][2][3]. Summary by Sections NCIB Program Details - The NCIB allows Microbix to repurchase up to 6,949,346 common shares, which is approximately 5% of the 138,986,931 shares outstanding as of November 26, 2025 [2]. - Repurchases will occur through the Toronto Stock Exchange (TSX) and alternative trading systems, with the actual number of shares repurchased determined by management [2][3]. - The maximum number of shares that can be repurchased in one day is set at 20,339, which is 25% of the average daily trading volume (ADTV) of 81,357 shares over the past six months [4]. Previous NCIB Performance - In the previous NCIB from December 9, 2024, Microbix sought approval to purchase up to 6,726,560 shares and successfully repurchased 3,661,581 shares at a volume-weighted average price of $0.369 [4]. Funding and Management Strategy - The repurchases will be financed from working capital, and all repurchased shares will be cancelled [5]. - Microbix has established a predefined automatic securities purchase plan with Ventum Financial Corp. to facilitate repurchases during internal trading blackout periods [5]. Board of Directors' Perspective - The Board believes that the current market price does not reflect the underlying value of Microbix, making the share repurchase an appropriate use of corporate funds [6]. - The NCIB is expected to benefit shareholders by increasing their proportionate equity interest as shares are cancelled [6]. Company Overview - Microbix Biosystems Inc. specializes in creating proprietary biological products for human health, generating revenues of C$ 25.4 million in its latest fiscal year [8]. - The company produces critical ingredients for the global diagnostics industry, including antigens for immunoassays and laboratory quality assessment products [8][10].

Core Viewpoint - Microbix Biosystems Inc. and Seegene Mexico are collaborating to enhance the availability of HPV testing and quality assessment products across Mexico, aiming to improve public health efforts in cervical cancer surveillance [1][6]. Group 1: Company Overview - Microbix Biosystems Inc. is a life sciences innovator that manufactures and exports biological products, including laboratory quality assessment products (QAPs) and reference materials, with revenues of C$ 25.4 million in its latest fiscal year [8][9]. - Seegene Mexico, established in 2016, is a subsidiary of Seegene Inc., a leader in multiplex PCR technology, focused on improving diagnostics for infectious diseases, particularly HPV [4][7]. Group 2: Product and Technology - The Allplex and Anyplex HPV 28 Detection assays developed by Seegene Mexico are real-time multiplexing PCR tests that can identify 19 higher-risk and 9 lower-risk HPV genotypes, providing critical infection status and genotype distribution information [3]. - The use of Microbix's QAPs will support the clinical implementation of Seegene's assays, ensuring that clinical labs in Mexico meet international quality standards [5][6]. Group 3: Market Impact - The collaboration is expected to significantly enhance cervical cancer surveillance efforts in Mexico, with a commitment from both companies to support continuous training and quality management systems in clinical laboratories [6][9].

Core Insights - Microbix Biosystems Inc. and SEKISUI Diagnostics, LLC are collaborating to support the U.S. commercialization of a molecular point-of-care assay for COVID/Flu A/Flu B using the Metrix platform [1][2][3] Company Overview - Microbix Biosystems Inc. specializes in creating proprietary biological products for human health, with revenues of C$ 25.4 million in its latest fiscal year and over 120 skilled employees [6] - SEKISUI Diagnostics, LLC has over 40 years of experience in providing innovative medical diagnostics globally, including clinical chemistry reagents and point-of-care tests [5] Product Details - The Metrix COVID/Flu Test is a 20-minute three-plex molecular assay that accurately detects SARS-COV-2, Influenza A, and Influenza B, showing 95-99% positive and negative concurrence with lab-based molecular assays [2][3] - The test is available in the U.S. under an Emergency-Use Authorization from the U.S. Food and Drug Administration [2] Collaboration and Support - Microbix is supplying SEKISUI with REDx™FLOQ quality assessment products (QAPs) to support the full patient-sample workflow of the Metrix Test, helping to avoid user errors [3][4] - The collaboration aims to enhance user training and compliance with quality systems, which is critical for customer support [4]

Core Insights - Microbix Biosystems Inc. is addressing a cybersecurity incident involving a ransomware attack that resulted in data theft but did not disrupt operations [1][2][3] - The company has been enhancing its cybersecurity measures since early 2022, including the implementation of advanced software systems [4][8] - Microbix has a policy of not paying ransoms to hackers, aiming to discourage cybercrime [4] Company Overview - Microbix is a life sciences innovator focused on creating proprietary biological products for human health, with over 120 employees and monthly revenues targeting C$ 2.0 million or more [5][6] - The company manufactures critical ingredients for the global diagnostics industry, including antigens for immunoassays and quality assessment products [5] - Microbix's products are sold in over 30 countries and are supported by a network of international distributors [5] Cybersecurity Measures - The company has adopted the Center for Internet Security (CIS) frameworks for its cybersecurity programs [8] - Regular employee cybersecurity training and endpoint server protection for real-time threat monitoring are part of the ongoing improvements [8] - Microbix is also focusing on disaster-recovery and business-continuity planning [8]